Sequential Endoluminal Gemcitabine and Cabazitaxel with Intravenous Pembrolizumab as a Bladder-Preserving Strategy for Docetaxel-Unresponsive Non-Muscle Invasive Urothelial Carcinoma Following Transurethral Resection of Bladder Tumor
Ian M. McElree(Vanderbilt University Medical Center), Michael A. O’Donnell(University of Iowa Health Care), Sarah L. Mott(University of Iowa Holden Comprehensive Cancer Center), Yousef Zakharia(University of Iowa), Helen Y. Hougen(University of Iowa), Ryan L. Steinberg(University of Iowa), Vignesh T. Packiam(Rutgers, The State University of New Jersey), Mohamad Abou Chakra(University of Iowa Health Care)
Cited by 7
Related Papers
Adjuvant atezolizumab versus observation in muscle-invasive urothelial carcinoma (IMvigor010): a multicentre, open-label, randomised, phase 3 trial
|The Lancet Oncology|2021|411
Comparison of Sequential Intravesical Gemcitabine and Docetaxel vs Bacillus Calmette-Guérin for the Treatment of Patients With High-Risk Non–Muscle-Invasive Bladder Cancer
|JAMA Network Open|2023|116
Optimized Management of Nivolumab and Ipilimumab in Advanced Renal Cell Carcinoma: A Response-Based Phase II Study (OMNIVORE)
|Journal of Clinical Oncology|2020|105